Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition.
about
Progress in systemic therapy of advanced hepatocellular carcinomaNon-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?State of the art management of metastatic gastroesophageal cancerResearch Progress of HGF/c-MET Inhibitor in the Treatment of Non-small Cell Lung CancerTargeting the epithelial to mesenchymal transition in glioblastoma: the emerging role of MET signalingProfile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to dateFrom molecular classification to targeted therapeutics: the changing face of systemic therapy in metastatic gastroesophageal cancerHepatocellular carcinoma: Where there is unmet needTubulin is a molecular target of the Wnt-activating chemical probePhase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma.A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumorsThe potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment.Systemic treatment of hepatocellular carcinoma: Past, present and futureIdentification of DW532 as a novel anti-tumor agent targeting both kinases and tubulin.Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib.c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancerHGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development.MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma.Targeting MET Amplification as a New Oncogenic Driver.The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer ModelsNovel agents in development for advanced non-small cell lung cancer.The evolving genomic classification of lung cancer.Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumorsMolecularly targeted therapies in non-small-cell lung cancer annual update 2014Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.New metastatic model of human small-cell lung cancer by orthotopic transplantation in mice.Aptamers Binding to c-Met Inhibiting Tumor Cell MigrationImproved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?Impact of MET targeting on tumor-associated angiogenesis and growth of MET mutations-driven models of liver cancer.Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma.Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancerUnderstanding drugs in breast cancer through drug sensitivity screeningCytotoxic activity of the MK2 inhibitor CMPD1 in glioblastoma cells is independent of MK2.A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapyGSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cellsOff-target effects of c-MET inhibitors on thyroid cancer cells.Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib.Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer.Targeting angiogenesis in renal cell carcinoma.Developing biomarkers to predict benefit from HGF/MET pathway inhibitors.
P2860
Q26740217-4ED77533-C79C-4C8A-8ECF-0E3557F98C5BQ26741814-B5049A41-AECD-4216-B70B-0483C3F34EABQ26779217-864E3AFE-86B0-4B51-9EFA-0DCA54E12674Q27006349-CA4C5B13-1E84-4907-A2A9-F6B799F9DF4FQ27011423-2481E4EC-D151-4FAE-AF7F-F3F96F86B736Q28071589-7121011F-F46A-4BB2-8D3A-B5E2E9A72461Q28082921-3C73BEB4-D5AD-4654-99FA-04D154AA4863Q28084046-9E64CFE5-9B48-47AD-A575-D192029372B9Q28833737-624FB1AC-D7B7-45CC-A021-AE1CD024B6F7Q33168449-82D1240E-6910-499E-99BA-B7FC5608F0C0Q33424270-1354414A-9E9A-49EB-B506-391B0B560AB4Q33769429-3DE89EA7-AE10-4508-AC69-FAC384BECFFCQ33854034-E6A740B2-2DDD-4291-BFF0-2CB157294BBFQ33869726-46BB3326-4AF8-48CC-944C-9309A2A54E78Q33880542-45421E6A-9F44-49B8-BAFA-2058CD3E1BB4Q33886974-3D5884B8-4080-4124-BA9B-34B65E0465CDQ33917507-C9D96FD4-9193-4C49-83F0-5CED3ED04872Q34182679-55D54839-F2A3-4C4A-81BE-46A32D1EE7FAQ34309927-E2CC0F38-37F0-4972-ADA0-FF5C5F48FD68Q34309954-52C6C3C9-157C-4B00-A659-4C8B3A00E50CQ34389263-DCD5CD28-98BB-49E5-ADDB-8F1E679A04B1Q34852043-2FF1C738-AF07-4FA4-A494-1025D0F47420Q34964958-0C76BCBE-6D21-41B9-97F7-7579E66814D3Q35136424-82B2D0CE-8CD0-4C07-8757-54E9247C66BDQ35214544-D016E7E5-5B0E-40CE-A56D-7642E40B3DD6Q35538433-C109075B-91F1-499F-B74C-D3ABFA89AF37Q35866739-0A440A10-1EC6-4B41-9263-ACDB2F004761Q35896530-D08E8EC3-6A1C-45E7-9DE2-1003C9CCC3E8Q36075407-718B87DC-8C96-4DE4-9360-D75A283878DEQ36156854-5375F854-CE00-4CC2-8BB8-C4479A1DB968Q36169304-90344155-AC64-4339-A70E-2FCFE65142C1Q36234079-FA0B9711-2177-4A1A-983A-2F4D74A4DFD2Q37164205-141C69A5-FBA2-4463-BADF-5A6C1BA7BCC2Q37352435-6A6F5F0C-87D2-4B52-9499-243414956F3CQ37620336-45CDEA45-1906-481F-BF1C-B546BFF7B2E2Q37625880-2B6E30A3-852A-4DE7-98FB-44975534F25AQ37687269-42D1E5F6-C433-4976-A683-6CD69484896FQ37743107-C7FFE4ED-F267-4512-A237-D58B9C8AE2A6Q38132231-35D6DD4C-7B5C-4D2D-9D61-74DF7B4FD073Q38150768-72BCD4B0-9ED6-4FEF-9169-1B266985EA90
P2860
Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 April 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition.
@en
Cytotoxic activity of tivantinib
@nl
type
label
Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition.
@en
Cytotoxic activity of tivantinib
@nl
prefLabel
Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition.
@en
Cytotoxic activity of tivantinib
@nl
P2093
P2860
P1433
P1476
Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition
@en
P2093
Aki Aoyama
Jeffrey A Engelman
Naoya Fujita
Takao Yamori
Tomoko Oh-hara
Youngchul Song
P2860
P304
P356
10.1158/0008-5472.CAN-12-3256
P407
P577
2013-04-18T00:00:00Z